Literature DB >> 8803685

Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption.

G Wallukat1, P Reinke, W V Dörffel, H P Luther, K Bestvater, S B Felix, G Baumann.   

Abstract

Immunoadsorption with Ig-Therasorb leads to a marked decrease in serum levels of immunoglobulins including of the agonist-like anti-beta 1-adrenoceptor autoantibody found in the serum of patients with idiopathic dilated cardiomyopathy. The reduction in autoantibody levels was accompanied by an improvement of heart function and a shift to a lower NYHA state. In this disease, as in a variety of other autoimmune disorders, apheresis with Ig-Therasorb led to a rapid improvement of the clinical status and could be used in end-stage dilated cardiomyopathy (with autoantibodies) as a bridge for transplantation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8803685     DOI: 10.1016/0167-5273(96)02598-3

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  20 in total

1.  Anti beta1-adrenoceptor autoantibodies analyzed in spontaneously beating neonatal rat heart myocyte cultures-comparison of methods.

Authors:  G Wallukat; E Nissen
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-03       Impact factor: 2.416

Review 2.  Current topics on therapeutic apheresis.

Authors:  Ken Yamaji
Journal:  J Artif Organs       Date:  2010-04-03       Impact factor: 1.731

3.  Effects of immunoadsorption on endothelial function, circulating endothelial progenitor cells and circulating microparticles in patients with inflammatory dilated cardiomyopathy.

Authors:  Daniel Bulut; Michael Scheeler; Lisa Marie Niedballa; Thomas Miebach; Andreas Mügge
Journal:  Clin Res Cardiol       Date:  2011-02-06       Impact factor: 5.460

4.  IgG subclass reactivity to human cardiac myosin in cardiomyopathy patients is indicative of a Th1-like autoimmune disease.

Authors:  P Skyllouriotis; M Skyllouriotis-Lazarou; S Natter; R Steiner; S Spitzauer; S Kapiotis; P Valent; A M Hirschl; S E Guber; G Laufer; G Wollenek; E Wolner; M Wimmer; R Valenta
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

Review 5.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

Review 6.  Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases.

Authors:  Gerd Wallukat; Ingolf Schimke
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

Review 7.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

Review 8.  Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure.

Authors:  Ziya Kaya; Hugo A Katus; Noel R Rose
Journal:  Clin Immunol       Date:  2009-05-14       Impact factor: 3.969

9.  Functional and structural characterization of anti-beta1-adrenoceptor autoantibodies of spontaneously hypertensive rats.

Authors:  Gerd Wallukat; Svenia Podlowski; Eberhard Nissen; Rosemarie Morwinski; Csaba Csonka; Arpad Tosaki; Ingolf E Blasig
Journal:  Mol Cell Biochem       Date:  2003-09       Impact factor: 3.396

10.  Immunoadsorption therapy for patients with dilated cardiomyopathy and heart failure.

Authors:  Uichi Ikeda; Hiroki Kasai; Atsushi Izawa; Jun Koyama; Yoshikazu Yazaki; Masafumi Takahashi; Makoto Higuchi; Chang-Sung Koh; Keiji Yamamoto
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.